Harrow Health, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.30% Shs Outstand27.35M Perf Week25.70%
Market Cap520.14M Forward P/E50.21 EPS next Y0.38 Insider Trans- Shs Float25.25M Perf Month32.49%
Income-22.60M PEG- EPS next Q-0.12 Inst Own52.80% Short Float / Ratio4.61% / 4.78 Perf Quarter62.34%
Sales88.50M P/S5.88 EPS this Y-432.70% Inst Trans-5.83% Short Interest1.16M Perf Half Y176.83%
Book/sh0.04 P/B478.25 EPS next Y156.70% ROA-23.00% Target Price19.62 Perf Year142.05%
Cash/sh1.81 P/C10.57 EPS next 5Y15.00% ROE-318.40% 52W Range5.40 - 19.19 Perf YTD27.91%
Dividend- P/FCF260.07 EPS past 5Y14.30% ROI3.40% 52W High-1.62% Beta0.20
Dividend %- Quick Ratio3.20 Sales past 5Y29.40% Gross Margin72.50% 52W Low249.63% ATR0.90
Employees182 Current Ratio3.50 Sales Q/Q21.90% Oper. Margin2.10% RSI (14)77.38 Volatility7.16% 5.09%
OptionableYes Debt/Eq0.00 EPS Q/Q23.10% Profit Margin-25.50% Rel Volume1.89 Prev Close19.13
ShortableYes LT Debt/Eq60.17 EarningsNov 14 AMC Payout- Avg Volume243.30K Price18.88
Recom1.70 SMA2026.37% SMA5039.10% SMA20092.94% Volume259,957 Change-1.31%
Sep-08-22Resumed B. Riley Securities Buy $17
Oct-14-21Resumed B. Riley Securities Buy $16
Sep-24-21Initiated Aegis Capital Buy $15
Jul-02-21Initiated Ladenburg Thalmann Buy $14.25
Feb-03-23 08:50AM
Feb-02-23 06:30AM
Jan-23-23 07:00AM
Jan-21-23 07:33AM
Jan-18-23 08:50AM
07:00AM Loading…
Jan-05-23 07:00AM
Dec-25-22 07:24AM
Dec-21-22 09:21AM
Dec-16-22 07:00AM
Dec-14-22 03:24PM
Nov-30-22 08:00AM
05:06AM Loading…
Nov-16-22 05:06AM
Nov-14-22 04:05PM
Nov-10-22 08:00AM
Oct-28-22 08:00AM
Oct-27-22 08:00AM
Oct-13-22 09:35AM
Oct-06-22 03:23PM
Oct-05-22 05:35PM
Sep-29-22 07:00AM
Sep-28-22 07:09AM
Sep-27-22 01:50PM
Sep-21-22 06:01PM
Aug-27-22 06:37PM
Aug-11-22 08:00AM
Aug-09-22 04:45PM
04:01PM Loading…
Jul-27-22 07:00AM
Jul-16-22 08:08AM
Jun-24-22 08:00AM
May-30-22 06:12AM
May-06-22 09:01AM
May-05-22 04:01PM
May-04-22 08:00AM
Apr-22-22 08:00AM
Apr-20-22 07:00AM
Mar-31-22 07:00AM
Mar-10-22 04:01PM
Feb-24-22 08:00AM
Feb-22-22 07:00AM
Feb-15-22 07:00AM
Feb-10-22 04:50PM
Feb-08-22 08:00AM
Feb-06-22 08:36AM
Jan-10-22 06:45AM
Jan-04-22 08:00AM
Dec-30-21 10:24AM
Dec-20-21 07:00AM
Dec-13-21 08:00AM
Dec-07-21 04:32PM
Dec-06-21 11:54AM
Nov-29-21 10:00AM
Nov-19-21 12:20PM
Nov-09-21 06:25PM
Nov-07-21 08:53AM
Oct-25-21 09:00AM
Sep-27-21 08:26AM
Sep-02-21 08:00AM
Aug-18-21 07:00AM
Aug-13-21 01:21AM
Aug-12-21 12:45PM
Aug-10-21 05:15PM
Aug-05-21 10:57AM
Aug-03-21 03:01PM
Aug-02-21 05:50PM
Jul-28-21 11:30AM
Jul-27-21 07:00AM
Jul-26-21 09:00AM
Jul-19-21 08:00AM
Jul-16-21 10:00AM
Jul-15-21 08:00AM
Jul-06-21 08:27AM
Jun-23-21 06:34AM
Jun-17-21 04:01PM
Jun-14-21 05:59PM
Jun-04-21 04:03AM
Jun-03-21 08:15AM
Jun-01-21 09:00AM
May-17-21 09:00AM
May-11-21 04:01PM
May-05-21 04:03PM
May-04-21 03:00PM
Apr-27-21 09:00AM
Apr-20-21 04:01PM
Apr-15-21 05:00PM
Apr-14-21 04:01PM
Apr-05-21 05:43AM
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOLL ANDREW R.Chief Financial OfficerDec 22Buy13.542,50033,850255,063Dec 23 07:02 AM
BAUM MARK LChief Executive OfficerDec 22Buy13.3925,000334,7501,432,141Dec 23 07:03 AM
Van Horn R. LawrenceDirectorDec 22Buy13.421,86024,9611,860Dec 23 07:00 AM
Makary Martin A.DirectorDec 21Buy13.3725,000334,25025,000Dec 23 07:01 AM
Opaleye Management Inc.10% OwnerDec 14Buy10.52431,1834,536,0453,600,000Dec 14 04:05 PM
LINDSTROM RICHARD L MDDirectorSep 30Sale12.6240,000504,80026,100Oct 03 06:02 PM
Opaleye Management Inc.10% OwnerSep 28Buy9.7711,085108,3543,185,000Sep 30 06:15 AM
Opaleye Management Inc.10% OwnerApr 13Buy6.7612,83286,7853,175,000Apr 13 06:33 PM
Opaleye Management Inc.10% OwnerApr 12Buy6.7528,557192,7173,165,000Apr 13 06:33 PM